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Abstract
Schizophrenia is ahighlyheritable disorder. Genome-wide association studies based largelyon commonalleleshave identiﬁedover
100 schizophrenia risk loci, but it is also evident from studies of copy number variants (CNVs) and from exome-sequencing studies
that rare alleles are also involved. Full characterization of the contribution of rare alleles to the disorder awaits the deployment of
sequencing technology in very large sample sizes, meanwhile, as an interim measure, exome arrays allow rare non-synonymous
variants to be sampled at a fraction of the cost. In an analysis of exome array data from 13 688 individuals (5585 cases and 8103
controls) from the UK, we found that rare (minor allele frequency < 0.1%) variant association signal was enriched among genes that
map to autosomal loci that are genome-wide signiﬁcant (GWS) in common variant studies of schizophrenia genome-wide
association study (PGWAS = 0.01) as well as gene sets known to be enriched for rare variants in sequencing studies (PRARE = 0.026).
We also identiﬁed the gene-wise equivalent of GWS support forWDR88 (WD repeat-containing protein 88), a gene of unknown
function (P= 6.5 × 10−7). Rare alleles represented on exome chip arrays contribute to the genetic architecture of schizophrenia, but as
is the case for GWAS, very large studies are required to reveal additional susceptibility alleles for the disorder.
Introduction
Schizophrenia is a severe psychiatric disorder with a lifetime risk
of ∼1% (1). High heritability points to amajor role for inherited al-
leles in the aetiology of the disorder (1,2); based on recent genom-
ic studies, it appears that the mode of inheritance essentially
adheres to a multifactorial model in which the genetic contribu-
tion is highly polygenic and in which very large numbers of risk
variants (>1000) are involved (1–4). Genome-wide association
studies (GWASs) have recently identiﬁed over a hundred risk
loci, yet cumulatively, under an additive model, these contribute
only ∼3.5% of the total population variance in liability (5). Ultim-
ately, around half to a third of the total genetic risk is thought to
be indexed by the sort of common alleles present onGWAS arrays
(3,6). How the remainder of the genetic liability to schizophrenia
is distributed across the allele frequency spectrum is still amatter
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of controversy, although undoubtedly, rare variants in the form
of CNVs, single-nucleotide variants (SNVs) and small insertion
deletions are involved (4). The effect sizes of the rare variants
that have so far been robustly implicated in the disorder are
large, with odds ratios typically ∼2–60 compared with about
≤1.1 for common alleles (7,8). There is no reason why large effect
sizes should be a general property of rare alleles; rather, there is
likely to be a bias with current studies being underpowered to
detect rare alleles that have low-effect sizes.
It is often challenging to draw biological inferences from com-
mon variant associations because this class of risk allele appears
to primarily exert its effects on regulating mRNA expression
or processing rather than through the protein structure (5,9).
Another complexity is that it is often not evidentwhich of several
possible candidate genes at an associated locus is responsible for
a given association. Taken together, thismeans it is unclear what
changes in biological function are likely to be indexed by the as-
sociation ﬁndings. This does not imply that GWAS studies cannot
provide the basis for biological insights, indeed common variants
have already pointed to several biological processes that are like-
ly involved, including for example the immune system (5).
Relatively few rare variants have been implicated in schizo-
phrenia to date. Nevertheless, studies of this class of variant
have been informative for providing clues about pathophysiology.
In particular, rare variant studies have highlighted proteins
involved in plasticity at glutamatergic synapses, especially the
activity-regulated cytoskeleton-associated protein (ARC) and N-
methyl--aspartate receptor (NMDAR) complexes, fragile X men-
tal retardation protein (FMRP) targets, and voltage-gated calcium
ion channels (10–13). Individual rare exonic alleles that are of rela-
tively high penetrance may be more informative than their com-
mon counterparts in so far as they may be easier to model in
animal and cellular systems. These considerations suggest that ir-
respective of any uncertainty surrounding their overall contribu-
tion to heritability, it is a reasonable hypothesis that the pursuit
of rare risk variants is an important focus for schizophrenia
research. At present, sequencing offers the only systematic ap-
proach to doing so in a comprehensive manner, but it is also
expensive. In the interim, cheaper ‘exome chip-based’ solutions
have been developed to allow exome-focused sampling of a
large number of rare exonic variants at a fraction of the cost of
sequencing.
Here, we describewhat is to date the largest systematic search
for uncommon non-synonymous genetic variation in schizo-
phrenia based on 13 688 individuals (5585 cases and 8103 con-
trols) from the UK genotyped using Illumina HumanExome
Arrays which are estimated to capture over 95% of the non-
synonymous variants that might be detected in an average Euro-
pean ancestry genome through exome sequencing (although it
does not cover de novo, private, previously unobserved or ex-
tremely rare variants; see the ‘Materials and Methods’ section
below). The case data set has already been evaluatedwith respect
to common genetic variation as part of the study from the Schizo-
phrenia Working Group of the Psychiatric Genomics Consortium
(PGC) (5). Therefore, here, we consider only the results for rela-
tively uncommon variants [minor allele frequency (MAF) < 1%].
Expecting low power to detect individual rare risk alleles even
in this sample, we also undertook gene and pathways based
tests. To maximize the signal-to-noise ratio for these multi-
locus tests, we based our analyses on alleles with MAF < 0.1%, a
class of alleles that captured most of the rare variants signal in
a recent exome-sequencing study of schizophrenia (10).
Results
Single-locus tests
For variants at MAF < 1%, the standardized genomic inﬂation
factor λ1000 was 0.8788. A quantile–quantile (QQ) plot is given in
SupplementaryMaterial, Figure S1. The test statistics are deﬂated
reﬂecting the presence the low power of regression tests for very
rare alleles. Table 1 gives the results for variants at P < 1 × 10−3,
Table 1. SNV association test results using logistic regression with 10 covariates, limited to P < 1 × 10−3 and MAF < 1%
SNV CHR Position (b37) MAF (%) MAF
Con (%)
MAF
Case (%)
MAF UK
Pop (%)
OR P GWS ANNOT Gene
rs140232654 1 111 739 856 0.47 0.35 0.72 0.45 2.12 1.91 × 10−5 N Missense DENND2D
rs74440117 7 97 863 152 0.16 0.068 0.29 0.19 4.1 6.01 × 10−5 N Missense TECPR1
rs74892550 16 3 707 191 0.75 0.61 0.99 0.69 1.66 0.00024 N Missense TRAP1, DNASE1
rs147802928 19 35 941 518 0.12 0.049 0.22 0.1 4.38 0.0003 N Missense FFAR2
rs146838872 9 12 694 094 0.07 0.019 0.16 0.074 9.56 0.0003 N Missense TYRP1
rs144338731 2 239 038 917 0.39 0.52 0.25 0.36 0.46 0.00044 N Missense ESPNL
rs36059660 20 36 640 870 0.92 0.75 1.2 0.88 1.56 0.00048 N Missense TTI1
rs118056333 8 70 515 476 0.78 0.64 1 0.68 1.61 0.0005 N Missense SULF1
rs61757580 7 13 737 4693 0.68 0.52 0.89 0.69 1.67 0.00059 Y Missense DGKI
rs116932219* 13 49 281 261 0.82 0.98 0.6 0.78 0.61 0.00066 N Missense CYSLTR2
rs34703321 12 122 361 711 0.94 1.1 0.73 0.99 0.63 0.00066 N Missense WDR66
rs79859029 16 31 927 353 0.24 0.17 0.38 0.2 2.3 0.00077 N Missense ZNF267
rs139049409 7 87 005 024 0.16 0.25 0.063 0.13 0.25 0.00078 N Stop CROT
rs149406506 10 104 231 098 0.12 0.2 0.036 0.13 0.17 0.0008 N Missense TMEM180
rs143085034* 13 49 281 101 0.81 0.97 0.6 0.77 0.61 0.00085 N Missense CYSLTR2
rs113141749 17 48 594 980 0.36 0.26 0.5 0.34 1.98 0.00089 N Missense MYCBPAP
rs55859133 16 30 128 265 0.16 0.099 0.26 0.17 2.82 0.00095 Y Missense MAPK3
rs35890409 12 57 569 339 0.76 0.61 0.95 0.68 1.59 0.00096 Y Missense LRP1
GWS indicates whether SNV is within one of the genome-wide signiﬁcant schizophrenia-associated regions reported by the PGC. Cluster plots for SNVs in this tablewere
visually inspected to ensure correct genotype calling. Positions given are for human genome build 37. Variants marked * are close together on the genome. The minor
alleles generally occur in the same samples, indicating that these markers are in strong LD. UK population MAF in column ‘MAF UK Pop’ taken from the UK Exome
Chip consortium website (http://diagram-consortium.org/uk-exome-chip/).
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and the results for all variants are given in SupplementaryMater-
ial, Table S1. No variant was genome-wide signiﬁcant (GWS).
Rare variants (n = 3) surpassing this threshold map to GWS
loci from the most recent schizophrenia meta-analysis (5) (GWS
threshold is P < 5 × 10–8). However, these cannot be considered as
strong candidates for being pathogenic mutations as they do not
even attain a relaxed corrected P-value threshold of 2.11 × 10−5
(allowing only for the 2371 markers with MAF < 1% that
map to the GWS regions). Since at no point in the QQ plot do
the test statistics signiﬁcantly elevate above the null, our
single-locus analyses are potentially consistent with a complete
absence of association signal captured by rare variation on the
present arrays.
For all results at P < 0.001, the MAF in the UK population lies
between the case and control MAF values, consistent with
inﬂated estimates of effect size at this end of the signiﬁcance
distribution as a result of the winners’ curse effect.
Gene set analysis
Seeking general evidence for an association signal in the exome
chip data, we applied a top down approach in which we ﬁrst ex-
amined two large gene-sets (the ‘Materials andMethods’ section)
that have been demonstrated to be enriched for schizophrenia
susceptibility genes (10,11). We reasoned that if the exome arrays
capture any schizophrenia associations, power to detect this
should be greater in this more limited, but rationally deﬁned,
gene set than in the genome as a whole.
Signiﬁcance for gene-set analyses of the subsets was cor-
rected by a Bonferroni correction for the number of tests. Both
GWAS and RARE subsets were enriched for rare-variant associ-
ation signal (Table 2). The GWAS set was further assessed for sig-
niﬁcance using 1000 phenotype-permuted optimized sequence
kernel-association test (SKAT-O) analyses, and remained signiﬁ-
cant (perm P = 0.01). This suggests that the exome-focused array
does indeed capture schizophrenia associations. Among the six
subsets of the RARE set, only the FMRP target setwas signiﬁcantly
enriched for rare variant associations, providing further evidence
that this set of genes is enriched for rare genetic variation of
relevance to schizophrenia. Removing SNVs present in the
FMRP target set from the larger RARE set abolished signiﬁcance
of enrichment (P = 0.245), suggesting that the signal in the RARE
set is driven primarily by the FMRP subset.
We tested all individual SNVs and geneswithin the above gene
sets for associationwith schizophrenia (QQ plot in Supplementary
Material, Fig. S2). Nonewas signiﬁcant after correcting formultiple
testing (according to thenumberof SNVsor geneswithineachset).
The broad gene-set enrichments are, therefore, not being driven
by a small number of highly signiﬁcantly associated SNVs or
genes.
We also carried out an exploratory SKAT-O analysis on a
combined pathway set consisting of 8680 gene sets taken from
the Gene Ontology, Kyoto Encyclopedia of Genes and Genomes,
National Cancer Institute, Mouse Genome Informatics, BioCarta,
Protein Analysis Through Evolutionary Relationships and Reac-
tome repositories (Supplementary Material, Table S2) (14–24). No
gene set approached signiﬁcance aftermultiple testing correction.
Genome-wide association tests
The gene-wide results for all genes with P < 0.001 are given in
Table 3 and a QQ plot depicting the results of gene-tests of the
12540 genes containing ≥2 non-synonymous SNVs at MAF < 0.
1% is shown in Supplementary Material, Figure S3. A Manhattan
plot of the gene results is shown in Supplementary Material,
Figure S4, and the complete set of gene results is given in Supple-
mentary Material, Table S3. None of the genes in Table 3 overlap
with any of the GWS regions found by the PGCmeta-analysis (5).
A single gene,WD Repeat Domain 88 (WDR88), reached the gene-
wide equivalent of genome-wide signiﬁcance (P < 2.5 × 10−6 =
0.05/20 000 correcting for ∼20 000 genes). Details of the seven
variants this result is based on are contained in Supplementary
Material, Table S4. Note that, two of the variants in the table
(exm1453363 and exm1453389) have no minor alleles in one
phenotype, and so are assigned P-values close to 1 by the sin-
gle-variant logistic regression association test. SKAT-O is not af-
fected by this issue. Manual inspection of cluster plots conﬁrmed
all calls were satisfactory, and multiple rare alleles were not car-
ried by any single individual implying, respectively, that the re-
sults are not driven by either by major genotyping error or by
non-independence of allele counts due to linkage disequilibrium.
Discussion
Most association studies of schizophrenia have focused on com-
mon variation, but studies of CNVs and, more recently, studies
based on exome sequencing, point to a contribution from rare
Table 2. Association analysis of gene sets using SKAT-O, limited to SNVs with MAF < 0.1%
Gene set P Number of tests Corr. P Number of genes Number of SNVs References
GWAS 0.01 2 0.02 335 1447 (5)
RARE 0.021 2 0.042 1865 17 456 (10–13)
RARE Subsets
ARC/NMDAR 0.29 6 1 51 294 (12)
ASD/ID de novo 0.26 6 1 665 7306 (11)
Calcium channels 0.38 6 1 19 176 (10)
FMRP targets 0.0048 6 0.029 644 6073 (13)
PSD (human core) 0.0792 6 0.42 401 2774 (10)
SCZ de novo hit genes 0.39 6 1 487 5645 (11)
SECONDARY ANALYSIS
RARE minus FMRP 0.25 1 0.25 1221 11 385 (10–13)
‘Number of genes’ column only includes those genes that contain at least one SNV that passes QC and has MAF < 0.1%. Corr. P is the P-value, Bonferroni corrected for the
number of tests at that level. GWAS set contains genes within the genome-wide signiﬁcant regions found by the PGC2 schizophrenia study. RARE set contains all genes
contained in six subsets—genes relating to the ARC/NMDAR complex, calcium channel genes, FMRP target genes, PSD genes, plus genes hit by de novo mutations in
schizophrenia or autism and intellectual disability. RARE minus FMRP set contains genes within these subsets other than FMRP target genes.
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variants.While rare variationmaymake only a small contribution
to the disorder in comparison with common variants (10), the
identiﬁcation of associated rare non-synonymous variants offers
advantages for translating genetic ﬁndings into biological under-
standing by, for example, implicating susceptibility genes more
precisely than common variant analysis, or by providing causal
mutations that may be more readily modelled in cellular and
animal systems.
An important downside of rare variant analysis is cost. It is
now clear that large samples on a scale similar to that used in
GWAS are, in general, necessary for robustly detecting rare
variation (25). However, sequencing, which is required to cata-
loguemost very rare variation, is at least 10 timesmore expensive
than fairly comprehensive GWAS arrays. This has motivated
interim measures seeking to identify a proportion of known
rare variation using cost-effective genotyping chip alternatives;
although they cannot capture private or previously unseen
variants, they can capture a proportion of recurrent previously
documented variation.
Whether current arrays have potential to capture variation
within the frequency spectrum relevant to schizophrenia is un-
clear given alleles with fairly large effects are under strong selec-
tion, and therefore are expected to be of very low frequency (26).
A recent sequencing studysuggests thatmost rare variant associa-
tions that couldpotentially bedetectable byexomesequencing are
found primarily at the very low frequency (MAF< 0.1%) end of the
spectrum, a frequency that is unfavourable for current arrays (10).
Moreover, supporting that, a study about half the size of the pre-
sent study and using an array with almost identical content was
unable to document any contribution toheritability from rare exo-
nic alleles (27). In this context, our observation of enrichment for
the rare-variant association signal in both of the tested primary
candidate gene sets is both novel and of practical importance.
Those observations suggest that while the total contribution
may be very small, rare variants (MAF < 0.1%) present on the
exome chip do contribute to the disorder. Hence, our study pro-
vides ground for optimism that rare variants in genes can be iden-
tiﬁed through the application of current exome array products to
samples equivalent in size to those in recent GWAS studies.
Such studies are already underway under the aegis of the PGC.
The ﬁndings further suggest that arrays with enhanced exome
variant coverage based on larger numbers of exome sequences,
particularly from individuals with neuropsychiatric disorders,
are likely to be informative.
Within the broad candidate gene categories, the only subcat-
egory that was signiﬁcantly enriched for the rare-variation asso-
ciation signal (nominally or corrected) was the FMRP target set.
The present ﬁndings add to what is now strong evidence, based
upon multiple study designs, that this gene set is enriched for
schizophrenia common variant associations (5) as well as for
rare mutations in schizophrenia, autism spectrum disorder
(ASD) and intellectual disability (10,11,28–30). Loss of FMRP in
Fragile X syndrome results in widespread deﬁcits in synaptic
plasticity. Accordingly, our ﬁndings extend the burgeoning
body of evidence that mechanisms underpinning plasticity are
involved in the pathogenesis of schizophrenia.
The othermain ﬁnding of note in the present studywas of the
association of a single gene, WDR88, at GWS level (corrected for
all genes). The function of WDR88 had not been characterized.
It belongs to a superfamily of 263 genes of diverse function,
only connected by the presence of WDR domains which form
β-propeller units at the protein level, giving no clue to the func-
tion of WDR88.
The implications of this ﬁnding for schizophrenia are there-
fore unclear. Moreover, as with common variant associations
that emerge as GWS in a single study, until it is supported by rep-
lication data this ﬁnding must be considered provisional.
In summary, the present study provides support for the hy-
pothesis that a proportion of the genetic architecture of schizo-
phrenia is accessible through current genotyping products,
supports the broad involvement of targets of FMRP in the dis-
order, and provides provisional evidence for WDR88 as a candi-
date schizophrenia susceptibility gene. However, as has been
the case with GWAS, very large studies are required to reveal
additional susceptibility alleles for the disorder.
Materials and Methods
Samples
Cases
Our cases were taken from two collections, Cardiff COGS and
CLOZUK (31), both of which have been described in the GWAS
study from the PGC (5) and which in that study were shown
to be typical of schizophrenia with respect to the heritability
conferred by common alleles. CLOZUK cases were taking the
antipsychotic clozapine. In the UK, patients taking clozapine pro-
vide blood samples to allow the detection of adverse drug-effects.
Through collaboration with Novartis (the manufacturer of a pro-
prietary form of clozapine, Clozaril), following ethical approval
and consistent with the UK Human Tissue Act, we acquired an-
onymous blood samples from people with treatment-resistant
schizophrenia as recorded by the treating psychiatrists on the
clozapine registration forms (31). Cardiff COGS cases were re-
cruited from communitymental health teams inWales and Eng-
land on the basis of a clinical diagnosis of schizophrenia or
schizoaffective disorder (depressed sub-type) as described previ-
ously (32). After informed written consent, diagnosis was subse-
quently established using the semi-structured schedules for
clinical assessment in neuropsychiatry (33) interview and review
of case notes followed by consensus diagnosis according to diag-
nostic and statistical manual of mental disorders-IV (34) criteria.
Controls
Two groups of UK controls were used in this study; UK Blood Ser-
vice donors (4455 samples) and the 1958 British Birth Cohorts
(4615 samples) (35–37). These samples have not been screened
for psychiatric illness, which for a disorder with the prevalence
Table 3. Gene SKAT-O results (P < 0.001) for SNVs with MAF < 0.1%
Gene Chr Start (b37) End (b37) P Number
of SNVs
WDR88 19 33 622 998 33 666 705 6.54 × 10−7 7
DSEL 18 65 173 819 65 184 217 2.61 × 10−5 13
DNAJC21 5 34 929 698 34 959 069 0.000139 8
DNAH11 7 21 582 833 21 941 457 0.000147 56
THAP4 2 242 523 820 242 576 864 0.000165 5
PIGG 4 492 989 533 985 0.00018 15
MYCL 1 40 361 098 40 367 925 0.000292 2
FAM186B 12 49 981 290 49 999 422 0.000392 17
GAB4 22 17 442 826 17 489 112 0.000661 11
ANGEL2 1 213 165 524 213 189 168 0.000717 2
GPR137 11 64 051 811 64 056 963 0.000734 2
Positions given are for human genome build 37. Cluster plots for SNVs in WDR88
were visually inspected to ensure correct genotype calling.
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of schizophrenia, has negligible impact on power. The study had
UK Multicentre Research Ethics Committee approval.
Genotyping
Genotyping was performed using the Illumina HumanExome
and HumanOmniExpressExome BeadChip arrays. Our analyses
were restricted to variants present on the HumanExome Bead-
Chip, which in turn is a subset of those on the HumanOmniEx-
pressExome BeadChip. The Illumina Exome BeadChip contains
247 870 genotyping probes, preferentially targeting rare coding
variants. The design of the probes was based on over 12 000 se-
quenced genomes and exomes. Non-synonymous variants that
have been observed at least three times (splice and start-stopmu-
tations at least two times) and are observed in two or more data
sets were considered for inclusion on the chip with additional
custom content (see http://genome.sph.umich.edu/wiki/Exome_
Chip_Design for full details).
All cases were typed at the Broad Institute (Cambridge, MA,
USA) while the controls were genotyped by the Wellcome Trust
Sanger Institute and The Broad Institute. Details of genotyping
site and array are given in Supplementary Material, Table S5.
The initial sample size was 6991 cases and 9070 controls.
Analysis
Quality control
First pass quality control (QC) was ﬁrst performed using PLINK on
genotypes called using GenCall (38,39). Initial QC for probe base
exclusions included Hardy–Weinberg equilibrium (HWE) P < 10−8,
call rate <98%, and non-autosomal location (Supplementary Ma-
terial, Table S6). Initial QC for subject exclusions were based on
call rate <98%, aswell as relatedness based on identity by descent
analysis, heterozygosity and principal component analysis (PCA)
(SupplementaryMaterial, Table S7). PCAwas run using Eigenstrat
based on 3022 SNPs with MAF > 1% (40,41). Cases and controls
were merged with 1100 samples from 11 populations using the
HapMap 3 data set (6), and outliers that did not cluster near to
the HapMap European individuals were removed to minimize
ancestral heterogeneity. In total we excluded 1204 cases, 735
controls and 16 841 markers prior to the zCall post-processing
procedure.
zCall is a post-processing step designed to improve the calling
of SNVs (42). We applied zCall to each batch (Supplementary Ma-
terial, Table S5) using batch-speciﬁc intensity data. Markers were
subsequently excluded if they were monomorphic, had call rates
<99%, had HWE P < 10−6 in any batch, or had a difference in call
rate between batches >1%.We also excluded probeswhere the al-
lele frequencies differed between the two groups of controls
(blood donors versus 1958 Birth cohort) at P < 0.001, or between
the cases assayed on the two types of chip at P < 0.0005. These
P-value thresholdswere derived fromQQ-plots of thewithin con-
trol and within case analyses. Finally, we excluded variants
which did not show a sufﬁcient difference in mean intensity be-
tween different genotype clusters (GenTrain score <0.4, cluster
separation metric <0.08) (Supplementary Material, Table S8).
We applied a further round of QC to the individuals based on
the Z-call genotypes, excluding samples on the basis of call rate
(>99% required for inclusion), heterozygosity (separately for var-
iants above and <1%MAF) and concordance betweendatabase and
genetically determined sex (Supplementary Material, Table S9).
The ﬁnal data set comprised 141 204 variants in 5585 cases and
8103 controls.
Allelic association test
Allelic association testing was performed in PLINK using logistic
regression (38). We adjusted for the population structure using
the ﬁrst 10 principle components as covariates. For comparison
(but not included in formal analyses), the minor allele frequency
for each variant in a sample of 55 276 Europeans from the UK
was downloaded from the UK Exome Chip Consortium (http://
diagram-consortium.org/uk-exome-chip/).
Gene-set and gene-wise tests
Variants were allocated to genes according the RefSeq database.
Genes and gene sets were examined using the uniﬁed method
implemented in SKAT-O, where rare effects were tested by ﬁnd-
ing the optimal linear combination of the burden and SKAT tests
(43). As in single-locus analyses, we used ten principal compo-
nents as covariates to account for population structure within
the sample. Analyses were restricted to non-synonymous var-
iants (missense, splice and nonsense) with MAF < 0.1%.
Our primary gene-set hypotheses concerned two broad sets
(Table 2) that are enriched for schizophrenia susceptibility
genes based on prior independent evidence from either common
(GWAS set) or rare (RARE set) variation. The GWAS set contained
all genes (n = 335) within the 105 autosomal GWS loci reported by
the psychiatric genetics consortium (5), excluding the extended
multiple histocompatibility complex regionwhich contains hun-
dreds of genes. The RARE set is a large composite candidate gene-
set (n = 1865) comprising six gene-sets that have been shown in
sequencing studies to be enriched for rare mutations in schizo-
phrenia (10,11). These include four gene-sets based upon the bio-
logical function: voltage calcium channel genes, genes repressed
by FMRP, members of the ARC and NMDAR complexes and genes
from the PSD-95 complex. The RARE set also contains a gene-set
containing genes affected by de novomutations in schizophrenia
case samples fully independent of those used in the current
study, and a second gene-set containing genes affected by
de novomutations in people with other neurodevelopmental dis-
orders, speciﬁcally, ASD and intellectual disability (ID) (10,11,28–
30). These disorders were chosen because there is some overlap
between associated rare variants in ASD, ID and schizophrenia
(11). See Table 2 for summary details and Supplementary Mater-
ial, Table S10 for gene and SNV membership of the candidate
gene-sets.
Tests of individual genes were limited to those with two or
more non-synonymous variants with MAF < 0.1%, a total of
12540 genes spanned by 77 446 variants. To obtain an empirical
P-value for the enrichment for rare variants in the GWAS gene
set, we randomly permuted (n = 1000) the case/control status of
individuals in the Exome chip data set and ran the gene-wide
SKAT-O analyses for the GWAS data set for each permutation. It
was computationally prohibitive to obtain empirical P-values for
the larger signiﬁcant data sets (RARE and FMRP).
Power
With the proviso of representation on the arrays, and specifying
an effect size that is approximately typical of known pathogenic
CNVs [odds ratio (OR) = 10] our single-locus tests have power of
90% to detect association to an allele with MAF > 0.04%, and of
25% for MAF > 0.02%. Assuming an OR of 2 (the lowest OR of a
known pathogenic CNV), appreciable power (25%) is only ob-
tained at MAF > 0.5% (which is the approximate MAF of the CNV
with theORof 2). Considering SNVswith aMAFof 0.1% andOR 1.6
(the average OR of SNVs with MAF > 0.075% and <0.125% in this
Human Molecular Genetics, 2016, Vol. 25, No. 5 | 1005
study), 80% power is achieved with a sample size of 27 786 cases
and 27 786 controls (44). However, these power calculations per-
tain for each individual locus. Under the hypotheses there are
many such loci, power to obtain at least one association of
many will be considerably higher.
Supplementary Material
Supplementary Material is available at HMG online.
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